Skip to content

Posts tagged ‘Mechanism of Action (MOA)’

Crizotinib and ALK rearrangements in lung cancer: an interview with Dr Ross Camidge

November 30th, 2010

Daedalus

Published by Sally Church on Pharma Strategy Blog